Compare BXC & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BXC | PHAT |
|---|---|---|
| Founded | 2004 | 2018 |
| Country | United States | United States |
| Employees | 1700 | 371 |
| Industry | Wholesale Distributors | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 706.5M | 590.6M |
| IPO Year | 2004 | 2019 |
| Metric | BXC | PHAT |
|---|---|---|
| Price | $73.79 | $7.12 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 12 |
| Target Price | ★ $88.33 | $20.45 |
| AVG Volume (30 Days) | 108.0K | ★ 1.1M |
| Earning Date | 11-03-2026 | 10-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 42.72 |
| EPS | ★ 0.62 | N/A |
| Revenue | N/A | ★ $175,110,000.00 |
| Revenue This Year | $5.56 | $80.50 |
| Revenue Next Year | $4.54 | $56.64 |
| P/E Ratio | $120.85 | ★ N/A |
| Revenue Growth | N/A | ★ 216.93 |
| 52 Week Low | $44.78 | $6.91 |
| 52 Week High | $93.80 | $18.31 |
| Indicator | BXC | PHAT |
|---|---|---|
| Relative Strength Index (RSI) | 41.00 | 37.55 |
| Support Level | $47.84 | $6.91 |
| Resistance Level | $81.73 | $9.74 |
| Average True Range (ATR) | 3.89 | 0.39 |
| MACD | -0.89 | -0.00 |
| Stochastic Oscillator | 2.14 | 23.18 |
BlueLinx Holdings Inc is engaged in the wholesale distribution of residential and commercial building products. Its business products are split into two categories: Structural products include items such as lumber, plywood, oriented strand board, rebar, and remesh, and Specialty products include items such as engineered wood, siding, millwork, outdoor living, specialty lumber and panels, and industrial products. The company's operations are carried out throughout the United States.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.